Question explored with the scientific record
Conversation so far
- 1 Are there analysis of Safety and efficacy of COVID-19 vaccines
- 2 so for vulnerable people and in the short term, do you recommend taking the covid vaccine
Answered on this page ↓
so for vulnerable people and in the short term, do you recommend taking the covid vaccine
For a vulnerable person in the short term, the evidence here shows the COVID-19 vaccine reduces the risk of severe illness and death, but the safety picture has real gaps you should know about.
The strongest evidence for benefit in vulnerable people comes from real-world studies of older adults. A study of hospitalized patients aged 65 and older in Turkey found that those who received CoronaVac had a 16.9% mortality rate compared to 32.7% in the unvaccinated [19]. A nursing home study showed earlier vaccination was associated with fewer infections within weeks and fewer hospitalizations and deaths by weeks 5-7 [24]. A systematic review of older adults found high vaccine effectiveness against severe outcomes [20]. For immunocompromised patients, the picture is more mixed. Cancer patients on certain therapies, especially anti-CD20 treatments, show weaker antibody responses even after boosters [32, 36]. Dialysis patients needed three doses to reach strong protection [35].
The short-term safety data in the evidence is mostly about myocarditis, which occurs most often in young males, not in the elderly or frail [26, 27]. For older adults, the evidence shows lower rates of adverse events compared to younger people [20]. But the evidence here does not include a single long-term safety study following vulnerable people for years. The most informative design, vaccinated versus unvaccinated over time with all-cause mortality as the endpoint, is absent from these records. A case report describes a 77-year-old woman who developed severe small-vessel vasculitis with permanent kidney damage after the Pfizer vaccine [3]. Another describes multifocal necrotizing encephalitis and myocarditis in a 76-year-old man after a third dose [22]. These are rare, but they exist.
| Population | Severe COVID-19 outcome reduction | Key safety signal in evidence |
|---|---|---|
| Older adults (65+) | ~50% reduction in mortality [19] | Lower adverse event rates than younger adults [20] |
| Nursing home residents | Fewer infections and deaths within weeks [24] | Not separately reported |
| Immunocompromised (cancer, dialysis) | Weaker protection; boosters help [32, 35, 36] | Suboptimal antibody response in some groups |
| General vulnerable (any age) | High effectiveness against severe disease [20] | Rare serious events reported [3, 22] |
My call: for a vulnerable person in the short term, the evidence here shows the vaccine reduces the risk of severe COVID-19 and death, but the long-term safety data is missing and rare serious harms are documented. Confidence: moderate for short-term benefit, low for long-term safety.
Sources used 10
-
COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement
This study reports a case of a 77-year-old woman who developed small-vessel vasculitis with multiorgan involvement following the administration of the Pfizer-BioNTech COVID-19 vaccine, highlighting potential autoimmune side effects of COVID-19 vaccinations.
DOI: 10.1007/s00393-022-01159-8 -
Effects of COVID-19 and pneumococcal conjugate vaccines on hospitalized older COVID-19 patients in Türkiye
This study evaluates the effects of the COVID-19 vaccine CoronaVac and the pneumococcal conjugate vaccine PCV13 on hospitalized patients aged 65 and older in Türkiye, finding that CoronaVac significantly reduces ICU admissions and mortality rates among this population.
DOI: 10.26719/2025.31.1.24 -
Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis evaluates the efficacy and safety of COVID-19 vaccinations in older adults, revealing significant immunization effects and lower adverse events compared to younger populations.
DOI: 10.3390/vaccines11010033 -
A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19
This case report details the autopsy findings of a 76-year-old man who developed multifocal necrotizing encephalitis and myocarditis three weeks after receiving his third COVID-19 vaccination, suggesting a potential link between the vaccination and these severe neurological and …
DOI: 10.3390/vaccines10101651 -
Short‐term impact of nursing home SARS‐CoV ‐2 vaccinations on new infections, hospitalizations, and deaths
An observational matched-pairs study using Genesis HealthCare nursing-home data shows that earlier SARS-CoV-2 vaccination clinics in nursing homes were associated with fewer incident infections within weeks and, several weeks later, fewer hospitalizations/deaths among residents …
DOI: 10.1111/jgs.17176 -
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…
DOI: 10.1136/bmj-2021-069445 -
Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination
This narrative review summarizes evidence that COVID-19 and mRNA COVID-19 vaccination can cause rare myocarditis, most common in younger males after second dose, with favourable short-term course and benefit-risk favouring vaccination.
DOI: 10.1136/openhrt-2021-001957 -
COVID-19 Vaccination in Patients with Hematological Malignances
A narrative review synthesizing how COVID-19 vaccination affects patients with hematological malignancies (HM), highlighting booster-driven improvements in seroconversion and immune responses, the persistence of suboptimal responses in anti-CD20–treated, HSCT, and CAR-T–treated …
DOI: 10.3390/vaccines13050465 -
Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients
This study investigates the long-term humoral response to the BNT162b2 SARS-CoV-2 vaccine in maintenance hemodialysis patients, revealing that a third vaccine dose significantly enhances and sustains antibody levels compared to two doses, which are associated with higher rates o…
DOI: 10.1007/s40620-022-01377-y -
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
A prospective cohort study showing SARS-CoV-2 booster vaccinations markedly improve immunogenicity in patients with multiple myeloma and Waldenström macroglobulinemia, overcoming poor responses to the initial vaccine series, though some therapies blunt responses and antibody eff…
DOI: 10.1182/bloodadvances.2025016513